在阿尔茨海默氏病模型中准溶酶体功能障碍以缓解斑块沉积
bioRxiv : the preprint server for biology
|July 14, 2025
概括
在阿尔茨海默病 (AD) 中的溶解体功能障碍涉及神经aminidase 1 (Neu1) 和保护性蛋白/cathepsin A (PPCA). 它们的相互作用调节了粉样蛋白前体蛋白 (APP) 处理,为AD提供了治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 与异常的粉样蛋白前体蛋白 (APP) 处理和 lysosomal 功能受损有关.
- 溶解体功能障碍有助于AD中神经炎症和神经退行.
研究的目的:
- 研究 lysosomal多酶复合体 (LMC) 成员,神经aminidase 1 (Neu1) 和保护蛋白/cathepsin A (PPCA) 在 APP代谢中的作用.
- 探索针对AD中Neu1-PPCA轴的治疗潜力.
主要方法:
- 对人类AD大脑和5xFAD/Neu1-/-小鼠模型的分析.
- 调查Neu1缺乏和PPCA/Neu1共同表达对APP处理和溶酶体功能的影响.
- 在5XFAD小鼠大脑中利用AAV介导的基因传递.
主要成果:
- Neu1 缺乏导致酸保留在 APP 和分泌酶上,增加粉原分裂和 Aβ42 生产.
- Neu1 缺乏促进了溶酶体外细胞分裂,导致细胞外Aβ释放和神经炎症.
- 过度表达PPCA或Neu1-PPCA联合表达使化正常化,降低分泌酶活性,并减轻粉样斑块负担.
结论:
- Neu1和PPCA形成了一个关键轴,调节APP新陈代谢和溶酶体平衡.
- Neu1-PPCA轴代表了阿尔茨海默病的新型治疗点.
- 通过AAV介导的Neu1和PPCA的共同表达在减少AD病理学方面显示出希望.
相关概念视频
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673